B-Cell depletion in immune thrombocytopenia

Seminars in Hematology

Volumn 50, Issue SUPPL.1, 2013, Pages

  Godeau, Bertrand ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; B CELL ACTIVATING FACTOR; BELIMUMAB; CD20 ANTIGEN; CD22 ANTIGEN; CD40 LIGAND; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; EPRATUZUMAB; IMMUNOGLOBULIN; RITUXIMAB; THROMBOCYTE ANTIBODY; VELTUZUMAB;

ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; COMMON VARIABLE IMMUNODEFICIENCY; CONNECTIVE TISSUE DISEASE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFUSION RELATED REACTION; LOW DRUG DOSE; LYMPHOMA; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE FREE SURVIVAL; RELAPSE; RETREATMENT; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THROMBOCYTE COUNT; VIRUS REACTIVATION;

ANTIGENS, CD20; B-LYMPHOCYTES; HUMANS; THROMBOCYTOPENIA;

EID: 84877638431     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.03.014     Document Type: Article

References (51)

1. Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus 2011, 9:262-273.
2. Chong B.H. ITP: Tregs come to the rescue. Blood 2010, 116:4388-4390.
3. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol 2010, 47:170-179.
4. Sprague C.C., Harrington W.J., Lange R.D., Shapleigh J.B. Platelet transfusions and the pathogenesis of idiopathic thrombocytopenic purpura. J Am Med Assoc 1952, 150:1193-1198.
5. Stashenko P., Nadler L.M., Hardy R., Schlossman S.F. Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci U S A 1981, 78:3848-3852.
6. Weiner G.J. Rituximab: mechanism of action. Semin Hematol 2010, 47:115-123.
7. Edwards J.C., Szczepanski L., Szechinski J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
8. Ramos-Casals M., Sanz I., Bosch X., Stone J.H., Khamashta M.A. B-cell-depleting therapy in systemic lupus erythematosus. Am J Med 2012, 125:327-336.
9. Shanafelt T.D., Madueme H.L., Wolf R.C., Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003, 78:1340-1346.
10. Leandro M.J., Cambridge G., Ehrenstein M.R., Edwards J.C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:613-620.
11. Nazi I, Kelton JG, Larche M, et al. Persistent impairments in humoral and cellular immunity in patients with immune thrombocytopenia treated with rituximab: a sub-study of a randomized controlled trial. 2012; ASH 54th Annual Meeting, Atlanta, GA, abstr 492.
12. Cooper N., Stasi R., Cunningham-Rundles S., Cesarman E., McFarland J.G., Bussel J.B. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Br J Haematol 2012, 158:539-547.
13. Stasi R., Del Poeta G., Stipa E., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007, 110:2924-2930.
14. Stasi R., Cooper N., Del Poeta G., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008, 112:1147-1150.
15. Audia S, Samson M, Trad M, et al. Failure of rituximab in immune thrombocytopenia is associated with the activation of splenic CD8 T cells. 2012; ASH 54th Annual Meeting, Atlanta, GA, abstr 623.
16. Audia S., Samson M., Guy J., et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood 2011, 118:4394-4400.
17. Mahévas M, Patin P, Huetz F, et al. B-cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells with unique characteristics. J Clin Invest. 2013;123:432-42.
18. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001, 98:952-957.
19. Arnold D.M., Dentali F., Crowther M.A., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007, 146:25-33.
20. Godeau B., Porcher R., Fain O., et al. Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura. Results of a multi-center prospective phase 2 study. Blood 2008, 112:999-1004.
21. Auger S., Duny Y., Rossi J.F., Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol 2012, 158:386-398.
22. Zaja F., Baccarani M., Mazza P., et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010, 115:2755-2762.
23. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
24. Neunert C., Lim W., Crowther M., et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
25. Patel V.L., Mahévas M., Lee S.Y., et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012, 119:5989-5995.
26. Provan D., Butler T., Evangelista M.L., et al. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 2007, 92:1695-1698.
27. Zaja F., Battista M.L., Pirrotta M.T., et al. Lower dose rituximab is active in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2008, 93:930-933.
28. Zaja F., Vianelli N., Volpetti S., et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 2010, 85:329-334.
29. Mahévas M, Ebbo M, Audia S, et al. Cost effectiveness of rituximab given at fixed dose (1000 mg on days 1 and 15) compared to the standard regimen in adult's immune thrombocytopenia. 2012; 54th Annual Meeting, Atlanta, GA, abstr 2157.
30. Jones R.B., Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
31. Hasan A., Michel M., Patel V., et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol 2009, 84:661-665.
32. Elstrom RL, Seery C, Moll C, et al. Rituximab combined with 3 cycles of high dose dexamethasone improves response in patients with newly-diagnosed, persistent, and chronic immune thrombocytopenia (ITP). 2012; ASH 54th Annual Meeting, Atlanta, GA, abstr 3345.
33. Gottenberg J.E., Ravaud P., Bardin T., et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62:2625-2632.
34. Khellaf M., Godeau B. and the national reference center for the study of autoimmune cytopenia. The ITP-RITUX Cohort: rituximab in immune thrombocytoPenia. Clinical Trials.gov NCT01101295 April 5, 2010.
35. Cooper N., Arnold D.M. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 2010, 149:3-13.
36. Carson K.R., Evens A.M., Richey E.A., et al. Progressive multifocal leukoencephalop- athy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2008, 113:4834-4840.
37. Venna N., Gonzalez R.G., Camelo-Piragua S.I. case 11-2010-a 69-year-old woman with lethargy, confusion, and abnormalities on brain imaging. N Engl J Med 2010, 362:1431-1437.
38. Dunleavy K., Tay K., Wilson W.H. Rituximab-associated neutropenia. Semin Hematol 2010, 47:180-186.
39. Michel M., Chanet V., Galicier L., et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004, 83:254-263.
40. Ghanima W., Godeau B., Cines D.B., Bussel J.B. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012, 120:960-969.
41. Zaja F., De Vita S., Mazzaro C., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003, 101:3827-3834.
42. Terrier B., Amoura Z., Ravaud P., et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010, 62:2458-2466.
43. Gobert D., Bussel J.B., Cunningham-Rundles C., et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol 2011, 155:498-508.
44. van Meerten T., Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol 2010, 47:199-210.
45. Liebman HA, Saleh MN, Bussel JB, et al. Phase I/II study of monotherapy with subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. 2012; ASH 54th Annual Meeting, Atlanta, GA, abstr 622.
46. Zhu X.J., Shi Y., Peng J., et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood 2009, 114:5362-5367.
47. Kremer J.M., Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
48. Khraishi M., Russell A., Olszynski W.P. Safety profile of abatacept in rheumatoid arthritis: a review. Clin Ther 2010, 32:1855-1870.
49. Dillon S.R., Harder B., Lewis K.B., et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010, 12:R48.
50. Solanilla A., Pasquet J.M., Viallard J.F., et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005, 105:215-218.
51. Kuwana M., Nomura S., Fujimura K., Nagasawa T., Muto Y., Kurata Y., Tanaka S., Ikeda Y. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004, 103:1229-1236.